

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): November 26, 2014**

---

**Amedica Corporation**  
(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-33624**  
(Commission  
File Number)

**84-1375299**  
(IRS Employer  
Identification No.)

**1885 West 2100 South**  
**Salt Lake City, UT**  
(Address of principal executive offices)

**84119**  
(Zip Code)

**Registrant's telephone number, including area code: (801) 839-3500**

**Not applicable**  
(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

---

**Item 8.01 Other Events.**

On November 26, 2014, Amedica Corporation (“Amedica” or the “Company”) closed the previously announced firm commitment underwritten public offering of units (the “Offering”). Amedica has issued 11,441,646 units at a price to the public of \$1.14 per unit. Each unit consists of one share of Amedica common stock and one warrant to purchase one share of common stock. In addition, Amedica has issued an additional 1,716,246 warrants (each such warrant to purchase one share of common stock) pursuant to the exercise, in part, of the underwriters’ over-allotment option. The warrants have an exercise price of \$1.48 per share, may be exercised on a cashless basis and will expire five years from the date of issuance. Gross proceeds to Amedica are approximately \$13.0 million, before deducting underwriting discounts and commissions and estimated expenses payable by Amedica.

The pricing of the Offering was previously reported on a Form 8-K filed by the Company with the SEC on November 21, 2014 (File No. 001-33624), which is incorporated herein by reference.

Dawson James Securities, Inc. acted as sole book-running manager for the Offering. Copies of the final prospectus for the Offering may be obtained from Dawson James Securities, Inc., Attention: Prospectus Department, One North Federal Highway, 5th Floor, Boca Raton, FL 33432, e-mail: [mmaclaren@dawsonjames.com](mailto:mmaclaren@dawsonjames.com) or toll free at 866.928.0928

The securities described above were offered by Amedica pursuant to a registration statement on Form S-1 (File No. 333-199753) that was declared effective by the Securities and Exchange Commission on November 20, 2014. This report shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMEDICA CORPORATION

/s/ Kevin Ontiveros

Kevin Ontiveros

Chief Legal Officer, Corporate Secretary

Date: November 26, 2014